SLC14A1 and cancer: Additionally, Professor Ma and his colleagues discovered that in bladder cancer, patients with a high proportion of SLC14A1+ cancer-associated fibroblast (CAF) exhibited a poorer response to neoadjuvant chemotherapy and immunotherapy.